5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

著者: Fátima Cardoso, Shani Paluch–Shimon, Elżbieta Senkus, Giuseppe Curigliano, Matti Aapro, Fabrice André, C.H. Barrios, Jonas Bergh, G.S. Bhattacharyya, Laura Biganzoli, Frances Boyle, Maria João Cardoso, L.A. Carey, Javier Cortés, Nagi S. El Saghir, Mona Elzayat, Alexandru Eniu, Lesley Fallowfield, Prudence A. Francis, Karen A. Gelmon, Joseph Gligorov, Renate Haidinger, Nadia Harbeck, Xin Hu, Bella Kaufman, Rajneesh Kaur, Belinda E. Kiely, S.-B. Kim, NU Lin, Shirley Mertz, Silvia P. Neciosup, B.V. Offersen, Shinji Ohno, Olivia Pagani, A. Prat, Frédérique Penault‐Llorca, Hope S. Rugo, G. W. Sledge, Christoph Thomssen, D.A. Vorobiof, Theresa Wiseman, Binghe Xu, Larry Norton, A. Costa, Eric P. Winer - Annals of Oncology 2020 被引用: 1,356

For the purpose of advanced breast cancer (ABC) guidelines, ABC comprises both inoperable locally advanced breast cancer (LABC) and metastatic breast cancer (MBC).1,2 Advanced/metastatic breast cancer remains a virtually incurable disease, with a median overall survival (OS) of about 3 years and a 5-year survival rate of around 25%,3,4 even in countries without major accessibility problems. Survival is strongly related to breast cancer subtype, with the major advances seen in human epidermal growth factor receptor 2 (HER2)-positive ABC.